DONAFENIB MESYLATE

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H16ClF3N4O3.CH4O3S
Molecular Weight	563.949
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CS(O)(=O)=O.[2H]C([2H])([2H])NC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1

InChI

InChIKey=IYEOGVPDPILUDO-NIIDSAIPSA-N

InChI=1S/C21H16ClF3N4O3.CH4O3S/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25;1-5(2,3)4/h2-11H,1H3,(H,26,30)(H2,28,29,31);1H3,(H,2,3,4)/i1D3;

HIDE SMILES / InChI

Molecular Formula	C21H16ClF3N4O3
Molecular Weight	467.843
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	CH4O3S
Molecular Weight	96.106
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C118294 | https://clinicaltrials.gov/ct2/show/NCT03602495 | http://www.ncbi.nlm.nih.gov/pubmed/29979858

Donafenib (CM-4307) is a derivative of sorafenib, where [1H] hydrogens on the terminal methyl group are substituted by deuterium. The drug was developed by the Chinese company Suzhou Zelgen Biopharmaceuticals. Upon oral administration, donafenib binds to and blocks the activity of Raf kinase, and inhibits Raf-mediated signal transduction pathways. This inhibits cell proliferation in Raf-expressing tumor cells. In addition, donafenib may inhibit unidentified RTKs, and thus may further block tumor cell proliferation in susceptible tumor cells. Donafenib is being investigated in phase 3 clinical trials for the treatment of 131I-refractory differentiated thyroid cancer, advanced hepatocellular carcinoma, and metastatic colorectal cancer.

Originator

Approval Year

C_max

Value	Dose	Analyte	Population
0.395 μg/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32008115/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	CM-4307 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.77 μg/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32008115/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	CM-4307 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.68 μg/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32008115/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	CM-4307 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2.58 μg/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32008115/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	CM-4307 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
4.94 μg/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32008115/	100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CM-4307 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
7.02 μg/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32008115/	200 mg 2 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CM-4307 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
6.95 μg/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32008115/	300 mg 2 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CM-4307 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
7.34 μg/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32008115/	400 mg 2 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CM-4307 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
14.5 μg × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32008115/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	CM-4307 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
54.1 μg × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32008115/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	CM-4307 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
62.3 μg × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32008115/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	CM-4307 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
102 μg × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32008115/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	CM-4307 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
40.6 μg × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32008115/	100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CM-4307 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
44 μg × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32008115/	200 mg 2 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CM-4307 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
41.5 μg × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32008115/	300 mg 2 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CM-4307 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
49.1 μg × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32008115/	400 mg 2 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CM-4307 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
23.9 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32008115/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	CM-4307 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
20.7 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32008115/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	CM-4307 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
27.8 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32008115/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	CM-4307 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
22.8 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32008115/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	CM-4307 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Substance Class	Chemical Created by `admin` on `Wed Apr 02 04:34:29 GMT 2025` Edited by `admin` on `Wed Apr 02 04:34:29 GMT 2025`
Record UNII	F3C1QUT2IS
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DONAFENIB MESYLATE

Common Name

English

CM-4307 MESYLATE

Preferred Name

English

DONAFENIB MESILATE

Common Name

English

4-(4-((((4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)AMINO)CARBONYL)AMINO)PHENOXY)-N-(METHYL-D3)-2-PYRIDINECARBOXAMIDE METHYLSULFONIC ACID SALT

Systematic Name

English

Donafenib mesilate [WHO-DD]

Common Name

English

Code System Code Type Description

PUBCHEM

145722042

Created by admin on Wed Apr 02 04:34:29 GMT 2025 , Edited by admin on Wed Apr 02 04:34:29 GMT 2025

PRIMARY

SMS_ID

300000056432

Created by admin on Wed Apr 02 04:34:29 GMT 2025 , Edited by admin on Wed Apr 02 04:34:29 GMT 2025

PRIMARY

FDA UNII

F3C1QUT2IS

Created by admin on Wed Apr 02 04:34:29 GMT 2025 , Edited by admin on Wed Apr 02 04:34:29 GMT 2025

PRIMARY

Related Record Type Details


					41XGO0VS1U

DONAFENIB

PARENT -> SALT/SOLVATE

Amount:

Related Record Type Details


					41XGO0VS1U

DONAFENIB

ACTIVE MOIETY

Amount:

Details

SMILES

InChI

DescriptionSources: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C118294 | https://clinicaltrials.gov/ct2/show/NCT03602495 | http://www.ncbi.nlm.nih.gov/pubmed/29979858

Originator

Approval Year

Cmax

AUC

T1/2

Description
Sources: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C118294 | https://clinicaltrials.gov/ct2/show/NCT03602495 | http://www.ncbi.nlm.nih.gov/pubmed/29979858

C_max

T_1/2